Bahl & Gaynor Inc Eli Lilly & CO Transaction History

Bahl & Gaynor Inc

$17.9 Billion
Q1 2024

A detailed history of Bahl & Gaynor Inc transactions in Eli Lilly & CO stock. As of the latest transaction made, Bahl & Gaynor Inc holds 877,799 shares of LLY stock, worth $803 Million. This represents 3.81% of its overall portfolio holdings.

Number of Shares

877,799

Previous 896,569 2.09%

Holding current value

$803 Million

Previous $523 Million 30.67%

% of portfolio

3.81%

Previous 3.15%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$592.2 - $792.28 $11.1 Million - $14.9 Million	-18,770 Reduced 2.09%	877,799 $683 Million
Q4 2023 Feb 02, 2024	SELL	$525.19 - $619.13 $20.2 Million - $23.8 Million	-38,504 Reduced 4.12%	896,569 $523 Million
Q3 2023 Nov 03, 2023	SELL	$434.7 - $599.3 $12.2 Million - $16.8 Million	-28,074 Reduced 2.91%	935,073 $502 Million
Q2 2023 Aug 14, 2023	SELL	$350.74 - $468.98 $50.9 Million - $68.1 Million	-145,114 Reduced 13.09%	963,147 $452 Million
Q1 2023 May 03, 2023	BUY	$310.63 - $364.82 $40.3 Million - $47.3 Million	129,726 Added 13.26%	1,108,261 $381 Million

Q4 2022 Feb 10, 2023	SELL	$321.55 - $374.67 $22.1 Million - $25.7 Million	-68,625 Reduced 6.55%	978,535 $358 Million
Q3 2022 Nov 14, 2022	BUY	$296.48 - $337.87 $18.8 Million - $21.4 Million	63,459 Added 6.45%	1,047,160 $339 Million
Q2 2022 Aug 08, 2022	BUY	$278.73 - $327.27 $32.2 Million - $37.9 Million	115,686 Added 13.33%	983,701 $319 Million
Q1 2022 May 12, 2022	SELL	$234.69 - $291.66 $75 Million - $93.3 Million	-319,727 Reduced 26.92%	868,015 $249 Million
Q4 2021 Feb 10, 2022	SELL	$224.85 - $279.04 $6.17 Million - $7.65 Million	-27,422 Reduced 2.26%	1,187,742 $328 Million
Q3 2021 Nov 15, 2021	BUY	$221.6 - $272.71 $5.38 Million - $6.62 Million	24,293 Added 2.04%	1,215,164 $281 Million
Q2 2021 Aug 06, 2021	BUY	$180.55 - $233.54 $6.2 Million - $8.02 Million	34,340 Added 2.97%	1,190,871 $273 Million
Q1 2021 May 11, 2021	BUY	$164.32 - $212.72 $830,966 - $1.08 Million	5,057 Added 0.44%	1,156,531 $216 Million
Q4 2020 Feb 02, 2021	BUY	$130.46 - $172.63 $6.81 Million - $9.01 Million	52,169 Added 4.75%	1,151,474 $194 Million
Q3 2020 Nov 12, 2020	SELL	$146.22 - $169.13 $1.45 Million - $1.67 Million	-9,893 Reduced 0.89%	1,099,305 $163 Million
Q2 2020 Aug 13, 2020	BUY	$136.42 - $164.18 $4.26 Million - $5.13 Million	31,258 Added 2.9%	1,109,198 $182 Million
Q1 2020 May 26, 2020	BUY	$119.05 - $147.35 $78.4 Million - $97 Million	658,443 Added 156.96%	1,077,940 $150 Million
Q1 2020 May 15, 2020	SELL	$119.05 - $147.35 $69.9 Million - $86.5 Million	-586,921 Reduced 58.32%	419,497 $58.2 Million
Q4 2019 Feb 14, 2020	BUY	$106.92 - $132.43 $28.9 Million - $35.7 Million	269,860 Added 36.64%	1,006,418 $132 Million
Q3 2019 Nov 14, 2019	SELL	$106.79 - $116.16 $15.8 Million - $17.2 Million	-148,185 Reduced 16.75%	736,558 $82.4 Million
Q2 2019 Aug 12, 2019	BUY	$110.79 - $129.32 $23.8 Million - $27.8 Million	214,787 Added 32.06%	884,743 $98 Million
Q1 2019 May 13, 2019	BUY	$111.31 - $131.02 $7.97 Million - $9.39 Million	71,644 Added 11.97%	669,956 $86.9 Million
Q4 2018 Feb 12, 2019	BUY	$105.9 - $118.64 $43.1 Million - $48.3 Million	406,912 Added 212.6%	598,312 $69.2 Million
Q3 2018 Nov 09, 2018	BUY	$85.86 - $107.31 $14 Million - $17.5 Million	163,091 Added 576.11%	191,400 $20.5 Million
Q2 2018 Aug 14, 2018	BUY	$75.7 - $86.88 $14,534 - $16,680	192 Added 0.68%	28,309 $2.42 Million
Q1 2018 May 11, 2018	SELL	$74.21 - $87.6 $85,786 - $101,265	-1,156 Reduced 3.95%	28,117 $2.18 Million
Q4 2017 Feb 13, 2018	BUY	$81.94 - $87.89 $29,170 - $31,288	356 Added 1.23%	29,273 $2.47 Million
Q3 2017 Nov 13, 2017	SELL	$77.07 - $85.54 $19,267 - $21,385	-250 Reduced 0.86%	28,917 $2.47 Million
Q2 2017 Aug 10, 2017	BUY	N/A	29,167	29,167 $2.15 Million

Others Institutions Holding LLY

# of Institutions

3,725

Shares Held

738M

Call Options Held

7.09M

Put Options Held

7.24M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $869B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bahl & Gaynor Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bahl & Gaynor Inc with notifications on news.

Account